ARTICLE | Company News

Bristol-Myers, Ono Pharmaceutical sales and marketing update

July 13, 2015 7:00 AM UTC

Opdivo nivolumab will be offered under the U.K.’s Early Access to Medicine Scheme (EAMS) to adults with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) who have undergone prior chemotherapy. The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) launched EAMS in March to provide patients who have life-threatening conditions with access to candidates that are not yet approved. ...